1. Home
  2. WRLD vs GYRE Comparison

WRLD vs GYRE Comparison

Compare WRLD & GYRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo World Acceptance Corporation

WRLD

World Acceptance Corporation

HOLD

Current Price

$158.01

Market Cap

646.0M

Sector

Finance

ML Signal

HOLD

Logo Gyre Therapeutics Inc.

GYRE

Gyre Therapeutics Inc.

HOLD

Current Price

$6.18

Market Cap

624.9M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
WRLD
GYRE
Founded
1962
2002
Country
United States
United States
Employees
N/A
618
Industry
Finance: Consumer Services
Biotechnology: Pharmaceutical Preparations
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
646.0M
624.9M
IPO Year
1994
2004

Fundamental Metrics

Financial Performance
Metric
WRLD
GYRE
Price
$158.01
$6.18
Analyst Decision
Strong Buy
Analyst Count
0
2
Target Price
N/A
$17.00
AVG Volume (30 Days)
153.9K
63.8K
Earning Date
04-30-2026
05-08-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
$564,841,465.00
$275,000.00
Revenue This Year
N/A
$19.88
Revenue Next Year
$6.51
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$110.00
$6.01
52 Week High
$185.48
$11.61

Technical Indicators

Market Signals
Indicator
WRLD
GYRE
Relative Strength Index (RSI) 63.42 34.28
Support Level $124.56 N/A
Resistance Level $163.80 $8.26
Average True Range (ATR) 6.23 0.38
MACD 0.63 -0.15
Stochastic Oscillator 97.26 10.31

Price Performance

Historical Comparison
WRLD
GYRE

About WRLD World Acceptance Corporation

World Acceptance Corp operates a small-loan consumer finance business. The company offers short-term small installment loans, medium-term larger installment loans, related credit insurance and ancillary products and services to individuals. It also offers income tax return preparation services to its loan customers and other individuals. The Company operates 1,024 branches in Alabama, Georgia, Idaho, Illinois, Indiana, Kentucky, Louisiana, Mississippi, Missouri, New Mexico, Oklahoma, South Carolina, Texas, Tennessee, Utah, and Wisconsin.

About GYRE Gyre Therapeutics Inc.

Gyre Therapeutics Inc is a commercial-stage biopharmaceutical company focused on the development and commercialization of small-molecule therapies for the treatment of organ fibrosis and inflammatory diseases. The company's commercial-stage products include ETUARY, Avatrombopag, and Nintedanib. In addition, it is focused on the development and commercialization of Hydronidone (F351) for the treatment of Metabolic Dysfunction Associated Steatohepatitis (MASH-associated liver fibrosis (MASH fibrosis). Gyre is also advancing a diverse pipeline of different drug candidates in China, including F573, F528, and F230. The company's reportable segments are Gyre Pharmaceuticals, which derives maximum revenue from the sale of ETUARY and certain generic drugs in the PRC, Gyre, and Other.

Share on Social Networks: